Breakthrough medicines. By design.

Cambium Bio is a patient-focused, clinical-stage, regenerative medicine company developing a pioneering platform in ophthalmology and tissue regeneration.

Therapeutic areas

Cambium Bio is advancing novel therapies for:

Dry Eye Disease (DED)

Knee Osteoarthritis

Wound healing

Our Science

Cambium Bio's proprietary technology platforms harness the regenerative potential of human platelet lysate and mesenchymal stem cells to develop innovative biologic therapies. Learn more about our science

Read More

Read More

Our Pipeline

Cambium Bio's diversified pipeline includes:

An illustration from Carlos Gomes Cabral
An illustration from Carlos Gomes Cabral
An illustration from Carlos Gomes Cabral

01.

Elate Ocular®

Elate Ocular®, a late clinical-stage asset for dry eye disease.

02.

Progenza

03.

Sygenus

See Our Pipeline

See Our Pipeline

Stay up to date

Sign up for alerts on our latest news, events, and ASX announcements.